Metabolomics profiling in prediction of chemo-immunotherapy efficiency in advanced non-small cell lung cancer

Mei, Lihong; Zhang, Zhihua; Li, Xushuo; Yang, Ying; Qi, Ruixue

doi:10.3389/fonc.2022.1025046

Cited by 3 publications

(1 citation statement)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Metabolomics profiling using gas chromatography mass spectrometry can predict the efficacy of chemotherapy and immunotherapy in patients with non-small cell lung cancer and shows that key metabolic pathways in response to chemotherapy and immunotherapy include glutamate metabolism, the glucose-alanine cycle, the urea cycle, etc. [96].…”

Section: Mass Spectrometry-based Metabolomics For Monitoring Treatmentsmentioning

confidence: 99%

Metabolomics for Clinical Biomarker Discovery and Therapeutic Target Identification

Lin,

Tian,

Guo

et al. 2024

Molecules

View full text Add to dashboard Cite

As links between genotype and phenotype, small-molecule metabolites are attractive biomarkers for disease diagnosis, prognosis, classification, drug screening and treatment, insight into understanding disease pathology and identifying potential targets. Metabolomics technology is crucial for discovering targets of small-molecule metabolites involved in disease phenotype. Mass spectrometry-based metabolomics has implemented in applications in various fields including target discovery, explanation of disease mechanisms and compound screening. It is used to analyze the physiological or pathological states of the organism by investigating the changes in endogenous small-molecule metabolites and associated metabolism from complex metabolic pathways in biological samples. The present review provides a critical update of high-throughput functional metabolomics techniques and diverse applications, and recommends the use of mass spectrometry-based metabolomics for discovering small-molecule metabolite signatures that provide valuable insights into metabolic targets. We also recommend using mass spectrometry-based metabolomics as a powerful tool for identifying and understanding metabolic patterns, metabolic targets and for efficacy evaluation of herbal medicine.

show abstract

Section: Mass Spectrometry-based Metabolomics For Monitoring Treatmentsmentioning

confidence: 99%

Metabolomics for Clinical Biomarker Discovery and Therapeutic Target Identification

Lin,

Tian,

Guo

et al. 2024

Molecules

View full text Add to dashboard Cite

show abstract

Unveil Intrahepatic Cholangiocarcinoma Heterogeneity through the Lens of Omics and Multi-Omics Approaches

Porreca,

Barbagallo,

Corbella

et al. 2024

Cancers

View full text Add to dashboard Cite

Intrahepatic cholangiocarcinoma (iCCA) is recognized worldwide as the second leading cause of morbidity and mortality among primary liver cancers, showing a continuously increasing incidence rate in recent years. iCCA aggressiveness is revealed through its rapid and silent intrahepatic expansion and spread through the lymphatic system leading to late diagnosis and poor prognoses. Multi-omics studies have aggregated information derived from single-omics data, providing a more comprehensive understanding of the phenomena being studied. These approaches are gradually becoming powerful tools for investigating the intricate pathobiology of iCCA, facilitating the correlation between molecular signature and phenotypic manifestation. Consequently, preliminary stratifications of iCCA patients have been proposed according to their “omics” features opening the possibility of identifying potential biomarkers for early diagnosis and developing new therapies based on personalized medicine (PM). The focus of this review is to provide new and advanced insight into the molecular pathobiology of the iCCA, starting from single- to the latest multi-omics approaches, paving the way for translating new basic research into therapeutic practices.

show abstract

Multi-omics research progress in lung cancer

2024

View full text Add to dashboard Cite

Lung cancer is a malignant tumor that seriously threatens human health, which has become one of the major health concerns that people care. Clinically, lung cancer is divided into small-cell lung cancer and non-small cell lung cancer, with non-small cell lung cancer accounting for 80% -85% of all pathological types of lung cancer. With the research on lung cancer, it has been found that most cases of lung cancer are already in the advanced stage, so early diagnosis of lung cancer is crucial. With the development of high-throughput technology, multi-omics analysis has provided us with a large amount of data for studying lung cancer. The study has discovered the important roles of genomics, transcriptomics, proteomics, and metabolomics in lung cancer. Based on the comprehensive analysis of multi-omics for lung cancer, we can identify the crucial biomarkers that are beneficial for early diagnosis of lung cancer for providing a better prognosis. This review provides the research progress of various omics technologies in lung cancer, so as to understand the molecular prognosis of lung cancer in clinical practice.

show abstract

Metabolomics profiling in prediction of chemo-immunotherapy efficiency in advanced non-small cell lung cancer

Cited by 3 publications

References 27 publications

Metabolomics for Clinical Biomarker Discovery and Therapeutic Target Identification

Metabolomics for Clinical Biomarker Discovery and Therapeutic Target Identification

Unveil Intrahepatic Cholangiocarcinoma Heterogeneity through the Lens of Omics and Multi-Omics Approaches

Multi-omics research progress in lung cancer

Contact Info

Product

Resources

About